Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

AIDS Healthcare Foundation Challenges Gilead Over AIDS Drug Price Gouging of U.S. Government Programs on Stribild

February 1, 2013

The AIDS Healthcare Foundation (AHF) reported that Gilead Sciences, Inc. charges U.S. HIV patients $28,500 per year for the new HIV drug Stribild, in comparison to $16,600 per patient per year in Canada and European countries with price controls. AHF president Michael Weinstein questioned why Gilead was willing to charge U.S. government programs like ADAP and U.S. HIV patients 42 percent more per patient, per year than price-controlled countries with stronger economies.

When the FDA approved Stribild, a drug that combines four HIV medicines in one pill, in September 2012, Gilead immediately set the U.S. Wholesale Acquisition Cost (WAC) at $28,500. Stribild costs 35 percent more per patient, per year than Atripla, Gilead's best selling three-in-one combination drug.

The WAC for other Gilead drugs also went up in 2013: Atripla increased 6 percent to $1,878.23 per month; Complera went up 5.8 percent to $1,936.53; Emtriva rose by 5.5 percent to $478.45; and Viread increased 6 percent to $771.39.

Weinstein stated AHF challenged Gilead's pricing strategy to educate people in the United States about the cost of HIV medicines and to pressure Gilead into changing its U.S. pricing policies.

Back to other news for February 2013

Adapted from:
Rock Hill Herald Online (Rock Hill, S.C.)
01.29.2013


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More News and Analysis on HIV Drug Pricing

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement